Pfizer Inc. stock (US7170811035): oncology deal with Innovent and fresh JP Morgan view in focus

Pfizer Inc. shares trade in the United States against the backdrop of a new USD 10.5 billion global oncology collaboration with Innovent Biologics and a reiterated Neutral rating from JP Morgan with a USD 30 price target, keeping the pharmaceutical major in the spotlight for NYSE investors.

Pfizer Inc. is back in focus on the New York Stock Exchange as investors digest a new global oncology collaboration with Innovent Biologics worth up to USD 10.5 billion alongside a fresh look from a major Wall Street bank that kept its stance on the stock unchanged.

The U.S.-based pharmaceutical group, whose shares trade on the NYSE under the ticker PFE, announced on 05/31/2026 that it had entered a global partnership with China-headquartered Innovent Biologics to co-develop and commercialize up to 12 oncology programs, in a transaction that could reach USD 10.5 billion including milestones, according to a company press release and subsequent coverage by GuruFocus as of 05/31/2026.GuruFocus as of 05/31/2026

Under the terms reported, Innovent is set to receive a USD 650 million upfront payment from Pfizer with the potential to earn up to USD 9.85 billion in development, regulatory and commercial milestones, while certain programs will be co-developed and co-commercialized with shared costs and profits in the United States and Europe, highlighting Pfizer's continued push to reinforce its oncology franchise.BioSpectrum Asia as of 05/31/2026

On the home market in the United States, Pfizer stock most recently closed at USD 26.18 on 05/31/2026 on the NYSE, while the latest analyst snapshot from MarketScreener shows an average target price of about USD 29.19, underscoring a modest gap between the market price and the consensus view.MarketScreener as of 06/01/2026

As a secondary reference point for German-speaking investors, Pfizer shares are also tradable on platforms such as Tradegate under the PFE symbol in euros, providing an additional access route beyond the primary U.S. listing for investors based in Germany.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Pfizer Inc.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology therapies, vaccines, cardiovascular and metabolic drugs, anti-infectives
• Home exchange/listing venue: New York Stock Exchange (PFE)
• Trading currency: USD

Pfizer Inc.: core business model

Pfizer focuses on researching, developing and marketing prescription medicines and vaccines across several therapeutic areas, with sales heavily influenced by the uptake and pricing of its oncology portfolio, immunology assets and established primary care brands.

What banks and research houses say about Pfizer Inc.

On the analyst side, JP Morgan reiterated its Neutral stance on Pfizer shares with an unchanged price target of USD 30 in a note dated 06/01/2026, according to a report from MarketScreener that cited analyst Chris Schott's latest view on the stock.MarketScreener as of 06/01/2026

The same MarketScreener overview as of 06/01/2026 indicates that the broader analyst community currently assigns Pfizer an average rating equivalent to Hold with a consensus target price close to USD 29.19, placing JP Morgan's USD 30 objective slightly above the aggregate but still within a relatively tight range for large-cap U.S. pharma coverage.MarketScreener as of 06/01/2026

Conclusion

The spotlight on Pfizer on 06/01/2026 is shaped by the significant USD 10.5 billion oncology collaboration it has agreed with Innovent Biologics and by trading on the NYSE that reflects a share price around the mid-USD-20 range as of the last close. The reiterated Neutral rating and USD 30 price target from JP Morgan, combined with a Hold-tilted consensus near USD 29.19, illustrate how major research houses are currently balancing the potential upside from pipeline and deal activity against execution and patent-expiry considerations without adopting a strongly directional stance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.